NCT00278668

Brief Summary

We suggest to investigate serotonin uptake in schizophrenia patients receiving ECT

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
15

participants targeted

Target at below P25 for all trials

Timeline
Completed

Started Oct 2006

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

January 16, 2006

Completed
2 days until next milestone

First Posted

Study publicly available on registry

January 18, 2006

Completed
9 months until next milestone

Study Start

First participant enrolled

October 1, 2006

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

October 1, 2006

Completed
Last Updated

May 21, 2008

Status Verified

May 1, 2008

First QC Date

January 16, 2006

Last Update Submit

May 20, 2008

Conditions

Schizophrenia

Eligibility Criteria

Age18 Years - 55 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64)

You may qualify if:

  • Participants must meet DSM-IV criteria for schizophrenia, as assessed by the Structured Clinical Interview - Patient Version (SCID) (First et al., 1995).
  • Ages 18 -55 Men and/or women -

You may not qualify if:

  • History of neurological disorders, active substance abuse in the previous 3 months.
  • Estimated IQ less then 70.
  • SSRIs treatment 4 weeks prior to the study.
  • Any subject suffering from inflammatory fever disease will be excluded from the study.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Schizophrenia

Condition Hierarchy (Ancestors)

Schizophrenia Spectrum and Other Psychotic DisordersMental Disorders

Study Officials

  • Avi Peled, MD

    Shaar Menashe MHC

    PRINCIPAL INVESTIGATOR

  • Ilan Modai, M.D. MHA

    Shaar Menashe

    PRINCIPAL INVESTIGATOR

  • Moshe Rehavi, Ph.D.

    TAU

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Avi Peled, MD

CONTACT

972522844050av_peled@netvision.net.il

Study Design

Study Type
observational
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER

Study Record Dates

First Submitted

January 16, 2006

First Posted

January 18, 2006

Study Start

October 1, 2006

Study Completion

October 1, 2006

Last Updated

May 21, 2008

Record last verified: 2008-05